Bone morphogenetic protein (BMP)-9 compositions and their uses

• US 6,034,062 A
• Filed: 03/13/1997
• Issued: 03/07/2000
• Est. Priority Date: 03/13/1997
• Status: Expired due to Fees

• Current Assignee: Genetics Institute LLC (Pfizer Inc.)
• Original Assignee: Genetics Institute LLC (Pfizer Inc.)
• Inventors: Song, Jeffrey J., Thies, R. Scott
• Primary Examiner(s): Kemmerer, Elizabeth
• Assistant Examiner(s): Romeo, David S.
• Application Number:
  US08/815,652
• Time in Patent Office: 1,090 Days
• Field of Search: 530/350, 530/399, 930/120, 514/12
• US Class Current: 514/8.8
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/51 Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: Y10S 930/12 Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Abstract

Purified Bone Morphogenetic Protein (BMP)-9 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair, and in hepatic growth and function.

Claims

1. A method for decreasing proliferation of kidney epithelial cells in a patient in need of same comprising the step of administering an amount of a BMP-9 protein encoded by a DNA sequence comprising a sequence selected from the group consisting of:

(a) nucleotides 124 through 453 of SEQ ID NO;

8;

(b) nucleotides 145 through 453 of SEQ ID NO;

8;

(c) nucleotides 610 through 1893 of SEQ ID NO;

1;

(d) nucleotides 628 through 1893 of SEQ ID NO;

1;

(e) nucleotides encoding amino acids 1 or 8 through 110 of SEQ ID NO;

9; and

(f) nucleotides encoding amino acids 1 or 8 through 110 of SEQ ID NO;

2 effective for decreasing proliferation of kidney epithelial cells to said patient.

2. A method for decreasing proliferation of lung epithelial cells in a patient in need of same comprising the step of administering an amount of a BMP-9 protein encoded by a DNA sequence comprising a sequence selected from the group consisting of:

(a) nucleotides 124 through 453 of SEQ ID NO;

8;

(b) nucleotides 145 through 453 of SEQ ID NO;

8;

(c) nucleotides 610 through 1893 of SEQ ID NO;

1;

(d) nucleotides 628 through 1893 of SEQ ID NO;

1;

(e) nucleotides encoding amino acids 1 or 8 through 110 of SEQ ID NO;

9; and

(f) nucleotides encoding amino acids 1 or 8 through 110 of SEQ ID NO;

2 effective for decreasing the proliferation of ling epithelial cells to said patient.

3. A method for inhibiting kidney tubule formation in a patient in need of same comprising the step of administering an amount a BMP-9 protein encoded by a DNA sequence comprising a sequence selected from the group consisting of:

(a) nucleotides 124 through 453 of SEQ ID NO;

8;

(b) nucleotides 145 through 453 of SEQ ID NO;

8;

(c) nucleotides 610 through 1893 of SEQ ID NO;

1;

(d) nucleotides 628 through 1893 of SEQ ID NO;

1;

(e) nucleotides encoding amino acids 1 or 8 through 110 of SEQ ID NO;

9; and

(f) nucleotides encoding amino acids 1 or 8 through 110 of SEQ ID NO;

2 effective for inhibiting kidney tubule formation to said patient.